A Business at a Glance
0 of 5 daily views used (5 remaining). Sign up free for 10 daily views, or try AAPL for a full preview.
Amgen Inc. (including its subsidiaries, referred to as “Amgen,” “the Company,” “we,” “our” or “us”) discovers, develops, manufactures and delivers innovative medicines to fight some of the world’s toughest diseases. We focus on areas of high unmet medical need and leverage our expertise to strive for solutions that dramatically improve people’s lives, while also reducing the social and economic burden of disease. We helped launch the biotechnology industry more than 45 years ago and have grown to be one of the world’s leading independent biotechnology companies. Our robust pipeline includes potential first-in-class medicines at all stages of development. We have a presence in approximately 100 countries worldwide. Amgen was incorporated in California in 1980 and became a Delaware corporation in 1987. Amgen operates in one operating segment: human therapeutics.
| Metric | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|---|
| Revenue | 36.8B | 36.8B | 33.4B | 28.2B | 26.3B | 26.0B |
| Net Income | 7.7B | 7.7B | 4.1B | 6.7B | 6.6B | 5.9B |
| EPS | $14.23 | $14.23 | $7.56 | $12.49 | $12.11 | $10.28 |
| Free Cash Flow | 8.1B | 8.1B | 10.4B | 7.4B | 8.8B | 8.4B |
| ROIC | 13.3% | 16.4% | 14.1% | 13.4% | 24.5% | 27.1% |
| Gross Margin | 67.2% | 67.2% | 61.5% | 70.0% | 75.7% | 75.2% |
| Debt/Equity | 6.84 | 6.84 | 10.83 | 10.60 | 11.07 | 4.98 |
| Dividends/Share | $9.46 | $9.66 | $9.13 | $8.64 | $7.95 | $7.22 |
| Operating Income | 9.1B | 9.1B | 7.3B | 7.9B | 9.6B | 7.6B |
| Operating Margin | 24.7% | 24.7% | 21.7% | 28.0% | 36.3% | 29.4% |
| ROE | 89.1% | 106.1% | 69.6% | 107.8% | 179.0% | 88.0% |
| Shares Outstanding | 542M | 542M | 541M | 538M | 541M | 573M |
AMGEN INC passes 5 of 9 quality checks, suggesting mixed fundamentals.
AMGEN INC trades at 24.6x trailing earnings, compared to its 15-year median P/E of 19.3x, suggesting it is currently Fair relative to its historical range. On a free-cash-flow basis, the stock trades at 23.3x vs a median of 13.3x. The company's 5-year average ROIC is 19.1% with a gross margin of 69.9%. Total shareholder yield (dividends) is 2.7%. At current prices, the estimated annualized return to fair value is +0.8%.
AMGEN INC (AMGN) has a current P/E ratio of 24.6, compared to its historical median P/E of 19.3. The stock is currently considered Fair based on its historical valuation range.
AMGEN INC (AMGN) has a 5-year average return on invested capital (ROIC) of 19.1%. This indicates strong capital allocation and a potential competitive advantage.
AMGEN INC (AMGN) has a market capitalization of $189.6B. It is classified as a large-cap stock.
Yes, AMGEN INC (AMGN) pays a dividend with a trailing twelve-month yield of 2.70%.
Based on historical P/E analysis, AMGEN INC (AMGN) appears fair. The current P/E of 24.6 is 27% above its historical median of 19.3. The estimated fair value CAGR (P/E method) is -1.7%.
AMGEN INC (AMGN) operates in the Biological Products, (No Diagnostic Substances) industry, within the Healthcare sector.
AMGEN INC (AMGN) reported annual revenue of $36.8 billion in its most recent fiscal year, based on SEC EDGAR filings.
AMGEN INC (AMGN) has a net profit margin of 21.0%. This is a strong margin indicating high profitability.
AMGEN INC (AMGN) generated $8.1 billion in free cash flow in its most recent fiscal year. Positive free cash flow supports dividends, buybacks, and debt reduction.
AMGEN INC (AMGN) has a debt-to-equity ratio of 6.84. This indicates higher leverage, which may increase financial risk.
AMGEN INC (AMGN) reported earnings per share (EPS) of $14.23 in its most recent fiscal year.
AMGEN INC (AMGN) has a return on equity (ROE) of 106.1%. This indicates the company generates strong returns for shareholders.
AMGEN INC (AMGN) has a 5-year average gross margin of 69.9%. This high margin suggests strong pricing power and a potential competitive moat.
The Ledger Terminal provides 19 years of financial data for AMGEN INC (AMGN), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
AMGEN INC (AMGN) has a book value per share of $15.98, based on its most recent annual SEC filing.